Health Catalyst (NASDAQ:HCAT) Price Target Lowered to $5.00 at Stifel Nicolaus

Health Catalyst (NASDAQ:HCAT) had its target price trimmed by Stifel Nicolaus from $10.00 to $5.00 in a research report report published on Thursday,Benzinga reports. The brokerage currently has a hold rating on the stock.

Other research analysts have also issued reports about the company. Stephens reiterated an “equal weight” rating and issued a $7.00 target price on shares of Health Catalyst in a report on Thursday. Wells Fargo & Company decreased their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Canaccord Genuity Group cut their target price on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada reduced their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 15th. Finally, KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.45.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $4.30 on Thursday. The firm has a 50 day moving average of $6.03 and a two-hundred day moving average of $7.24. The stock has a market capitalization of $261.46 million, a PE ratio of -3.18 and a beta of 1.34. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 52 week low of $3.76 and a 52 week high of $9.24.

Insider Activity

In other Health Catalyst news, insider Linda Llewelyn sold 6,441 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the transaction, the insider now owns 85,819 shares in the company, valued at $465,997.17. This represents a 6.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Benjamin Landry sold 19,268 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $160,309.76. Following the transaction, the general counsel now directly owns 72,250 shares in the company, valued at approximately $601,120. The trade was a 21.05 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 87,610 shares of company stock worth $664,043. Corporate insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HCAT. First Light Asset Management LLC boosted its holdings in shares of Health Catalyst by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company’s stock valued at $37,055,000 after acquiring an additional 944,631 shares during the period. Impax Asset Management Group plc raised its position in Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after purchasing an additional 195,525 shares during the last quarter. Daventry Group LP grew its position in Health Catalyst by 3.8% during the 4th quarter. Daventry Group LP now owns 2,509,480 shares of the company’s stock worth $17,742,000 after purchasing an additional 91,878 shares during the last quarter. Primecap Management Co. CA grew its position in Health Catalyst by 1.1% during the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Alyeska Investment Group L.P. increased its stake in Health Catalyst by 74.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock valued at $14,277,000 after purchasing an additional 861,150 shares during the period. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.